Morgan Stanley Upgrades Relypsa, Inc. (RLYP) to Equalweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Cantor Fitzgerald Downgrades Relypsa, Inc. (RLYP) to Hold
July 26, 2016 7:38 AM EDTCantor Fitzgerald downgraded Relypsa, Inc. (NASDAQ: RLYP) from Buy to Hold with a price target of $32.00 (from $41.00).
For an analyst ratings summary and ratings history on Relypsa, Inc. click here. For more ratings news on Relypsa, Inc. click here.
Shares of Relypsa, Inc. closed at $31.97 yesterday.
... MoreGalenica to Acquire Relypsa (RLYP) for $32/Share
July 21, 2016 5:42 AM EDTGalenica Group and Relypsa, Inc. (Nasdaq: RLYP) announced that the companies have entered into a definitive agreement under which Galenica will acquire Relypsa. This transaction further strengthens Galenicas Business unit, Vifor Pharma, as the company will gain full global rights to the potassium binder Veltassa (patiromer) for oral suspension and enhance its growing position as a global specialty pharmaceutical company. Under the terms of the merger agreement, Galenica will pay $32 per share in cash, or a total of approximately $1.53 billion. Through this acquisition, Vifor Pharma will gain a fully-integrated commercial organization in the United... More
